Legend Biotech has a target action date of February 28 for the company’s BLA for ciltacabtagene autoleucel (cilta-cel) for adults with relapsed and/or refractory multiple myeloma. The BLA was submitted by Legend’s collaboration partner, Janssen Biotech Inc., a Johnson & Johnson company.
The U.S. Food and Drug Administration approved Immunocore’s Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
AstraZeneca’s much anticipated cancer drug pipeline suffered a modest blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for a rare cancer […]
BOULDER, Colo., July 22, 2015 /PRNewswire/ — AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal […]